AXT to Bring Poietis Next-Gen Bioprinters to Australia

AXT are proud to announce that they have partnered with France-based Poietis to bring their next-generation bioprinting platforms to Australia.

The Poietis NGB-R next-generation bioprinter

The NGB (Next Generation Bioprinting) system is a world first using laser-assisted bioprinting technology to print cells (from aggregates and cellular spots to single cell) rapidly and precisely in complex cellular formations in 3D, maintaining a cell viability of 95%.

Poietis, established in 2014, are the result of 15 years of research and development. Their technology has shown immediate success with partnerships with companies such as BASF, Servier and L'Oréal to develop tissue models. Poietis have commercialised a skin model "Poieskin", a full-thickness printed skin used in drug testing and development.

Poietis bring the future of tissue engineering to your lab, helping you create actual, functional living tissues - not mere 3D scaffolds.

Antoine Jacquot, Sales Manager at Poietis commented on the new distributorship agreement with AXT, "we have already established an excellent reputation in Europe with our products and technology. We are looking forward to replicating the same success in Australia and New Zealand with the help of our partners at AXT.

Richard Trett, Managing Director of AXT said, "I believe bioprinting will have a revolutionary position in biomedical and biomaterials research. There are also seemingly limitless associated applications from drug testing to organ on a chip technology. Perhaps even more exciting, ultimately, are the clinical pathways that it promises. Biomedical and biomaterials is such an important field, especially in Australia and the Poietis technology and expertise will be of great benefit to researchers working in this area.

The addition of Poietis technology bolsters AXT's portfolio of solutions in the cellular biology, drug development and life science sectors. For more information, please visit



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AXT Pty Ltd. (2020, September 01). AXT to Bring Poietis Next-Gen Bioprinters to Australia. News-Medical. Retrieved on July 13, 2024 from

  • MLA

    AXT Pty Ltd. "AXT to Bring Poietis Next-Gen Bioprinters to Australia". News-Medical. 13 July 2024. <>.

  • Chicago

    AXT Pty Ltd. "AXT to Bring Poietis Next-Gen Bioprinters to Australia". News-Medical. (accessed July 13, 2024).

  • Harvard

    AXT Pty Ltd. 2020. AXT to Bring Poietis Next-Gen Bioprinters to Australia. News-Medical, viewed 13 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AXT and CELLINK Form a Formidable Australian Bioprinting Partnership